ALEC$1.82
Chart
Performance
Key Stats
AI ALEC Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
NeutralAlector is a clinical-stage biotechnology company focused on neurodegenerative diseases. While it has a promising pipeline and strategic partnerships, its current financial performance shows significant losses, and its stock price has experienced substantial volatility. The company's success is highly dependent on the clinical trial outcomes of its lead candidates. The current technical indicators are mixed, suggesting a neutral short-to-medium term outlook. Investors should approach with caution and a high-risk tolerance.
Thematic
Alector operates in the high-growth, high-risk biotechnology sector, specifically targeting neurodegenerative diseases like Frontotemporal Dementia (FTD) and Alzheimer's. The growing aging population globally and increased understanding of these complex diseases create a strong thematic tailwind. The company's focus on novel mechanisms of action, such as progranulin (PGRN) elevation, positions it within a critical unmet medical need.
Fundamental
Alector is currently in a pre-revenue or early-revenue phase, characterized by substantial operating expenses for research and development, leading to consistent net losses. Its financial position relies heavily on cash reserves and potential future funding or revenue from its pipeline assets. The company's debt levels are moderate, but its free cash flow is negative, indicating a burn rate that requires careful management.
Technical
Alector's stock price has shown significant volatility over the past year. While it is trading above its 200-day moving average, indicating a longer-term bullish trend, shorter-term indicators like the RSI suggest it is approaching overbought territory. The stock has experienced substantial price swings, and immediate price action may be influenced by news regarding clinical trial progress or regulatory updates.
| Factor | Score |
|---|---|
| Neurodegenerative Disease Treatment | 85 |
| Biotechnology Innovation | 80 |
| Strategic Partnerships | 90 |
| Regulatory Landscape | 70 |
| Competition | 65 |
| Factor | Score |
|---|---|
| Valuation | 40 |
| Profitability | 10 |
| Growth | 20 |
| Balance Sheet Health | 70 |
| Cash Flow | 25 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 55 |
| Volume Confirmation | 65 |
| Support & Resistance | 50 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Positive EPS Surprises
Alector (ALEC) has exceeded earnings per share (EPS) estimates in 9 out of the last 12 quarters, indicating consistent operational performance and effective cost management.
Sufficient Cash Reserves
Alector (ALEC) held $330.21 million in cash and cash equivalents as of Q4 2024, providing a buffer against short-term financial needs and supporting ongoing research and development.
Bearish Points (7)
Consistent Net Losses
Alector (ALEC) has reported net losses for the past several fiscal years (e.g., -$119.05M in 2024, -$130.39M in 2023), indicating ongoing unprofitability, which is common for clinical-stage biotechnology companies but presents a significant risk.
Negative P/E Ratio
Alector (ALEC) has a negative Price-to-Earnings (P/E) ratio (-2.1 TTM), which is typical for companies not yet generating profits, making traditional valuation methods less applicable and highlighting the speculative nature of the investment.
Calendar
August 2025
7
Next Earnings Date
H: $-0.35
A: $-0.47
L: $-0.54
H: 3.92M
A: 2.76M
L: 2.00M
Profile
Alector, Inc., a late-stage clinical biotechnology company, develops therapies that is focused on counteracting the devastating progression of neurodegenerative diseases. The company's products under development include Latozinemab (AL001), an investigational human recombinant monoclonal antibody designed to elevate progranulin (PGRN), a protein encoded by the granulin (GRN) gene that regulates lysosomal function, neuronal survival, and inflammation in the brain. Its lead PGRN-elevating candidate is being developed for the potential treatment of frontotemporal dementia with a granulin gene mutation (FTD-GRN) which is caused by heterozygous loss-of-function (LOF) mutations in the GRN gene and results in PGRN haploinsufficiency and is in Phase 3 clinical trial. It also develops AL101/GSK4527226 that is in Phase 2 clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. In addition, the company's preclinical and research pipeline products include ADP037-ABC, a proprietary anti-amyloid beta (Aß) antibody paired with proprietary ABC for the treatment of AD; ADP050-ABC, a GCase replacement therapy paired with proprietary ABC for GBA gene mutation carriers with Parkinson's disease and Lewy body dementia; ADP056, a Reelin modulator designed to block tau pathology and promote synaptic function in AD; and ADP063-ABC and ADP064-ABC that are therapeutic candidates paired with proprietary ABC that target tau pathology in AD through distinct approaches. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including latozinemab and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.
Seasonals
Price Target
4.65 USD
The 39 analysts offering 1 year price forecasts for ALEC have a max estimate of 10.00 and a min estimate of 1.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 95
Major biopharmaceutical company with a strong focus on neurological and neurodegenerative diseases, including Alzheimer's and MS. Direct competitor and potential collaborator.
Weight: 90
Major pharmaceutical company with a significant and advanced pipeline in Alzheimer's disease and other neurological conditions.
Weight: 88
Global pharmaceutical giant with a substantial presence and pipeline in neurology, including neurodegenerative disorders, and active partnering efforts.
Weight: 85
Clinical-stage biotechnology company directly focused on developing therapies for neurodegenerative diseases, often cited as a direct peer/competitor to Alector.